The Cellax technology was profiled in a recent issue of SciBX (subscription necessary). MaRS Innovation is mentioned in the article as the technology's commercialization agent.
Here's an excerpt:
"Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane in mouse models of breast cancer. The Ontario Institute for Cancer Research (OICR) is backing the program with $1.5 million to take it to the clinic. The expectation is that the product’s ability to target the tumor stroma rather than the ...
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog.
Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013.
The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ...
TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.
Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.
XLV’s solution has ...
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. This post coincided with World Cancer Day.
What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy?
Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver ...
MaRS Innovation's (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including:
MI and UHN's partnership with Stem Cell Therapeutics was covered in the magazine's Dealmakers subsection. Read the write-up on the Biotechnology Focus website.
Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine's Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research.
MaRS Innovation's ...
Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission
Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc., is developing the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on University of Toronto research by Professors Shana Kelley and Edward Sargent.
Today, Xagenic announced it has successfully closed a Series B financing round totaling $20 million. New investor Domain Associates, LLC, led the round, joined by existing investors who ...
TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.
The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund. (more…)